StemSynergy Therapeutics Inc. Now Accepting Applications for Expanded Access Protocols (EAPs) in Upcoming Clinical Trial
StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells
StemSynergy Therapeutics Provides Proof of Concept for Potential New Class of Cancer Drugs
StemSynergy Therapeutics Invited to Present at the NIH SBIR/STTR Innovation Zone at the BIO International Biotechnology Conferences (2014, 2020, 2024)
Stemsynergy Therapeutics Announces Breakthrough in Treating Sarcomas with Its Novel Anti-Wnt Compound
SSTI has a multidisciplinary team of scientists.
Meet the founders behind StemSynergy Therapeutics, Inc.
SSTI targets essential undrugged pathways in cancers.
